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Abstract
Background: In the last decade several authors have reviewed the features of pilot and feasibility studies and
advised on the issues that should be addressed within them. We extend this literature by examining published
pilot/feasibility trials that incorporate random allocation, examining their stated objectives, results presented and
conclusions drawn, and comparing drug and non-drug trials.
Methods: A search of EMBASE and MEDLINE databases for 2000 to 2009 revealed 3652 papers that met our search
criteria. A random sample of 50 was selected for detailed review.
Results: Most of the papers focused on efficacy: those reporting drug trials additionally addressed safety/toxicity;
while those reporting non-drug trials additionally addressed methodological issues. In only 56% (95% confidence
intervals 41% to 70%) were methodological issues discussed in substantial depth, 18% (95% confidence interval 9%
to 30%) discussed future trials and only 12% (95% confidence interval 5% to 24%) of authors were actually
conducting one.
Conclusions: Despite recent advice on topics that can appropriately be described as pilot or feasibility studies the
large majority of recently published papers where authors have described their trial as a pilot or addressing
feasibility do not primarily address methodological issues preparatory to planning a subsequent study, and this is
particularly so for papers reporting drug trials. Many journals remain willing to accept the pilot/feasibility
designation for a trial, possibly as an indication of inconclusive results or lack of adequate sample size.
Background
In the last decade a number of authors have reviewed the
justification for describing a trial as a pilot or feasibility
study in terms of its content and the questions it addresses
[1-5]. Lancaster et al [2] list as legitimate objectives of a
pilot study: sample size calculation; providing a dummy
run of trial procedures/the protocol; testing data collection
forms or questionnaires; testing how randomization proce-
dures work; determining recruitment and consent rates;
examining the acceptability of the intervention; and selec-
tion of the most appropriate primary outcome measure.
Thabane et al [5] categorize reasons to conduct a pilot
study into four groups: assessing the feasibility of pro-
cesses that are key to the success of the main study; asses-
sing time and resource problems; potential human and
data management problems; and scientific issues including
the assessment of treatment safety, dose, response effects
and variance of the effect. They also include a checklist of
items to include in reports of pilot studies. Arain et al [4]
recommend the NIHR Evaluation, Trials and Studies
Coordinating Centre definitions [6] which describe a pilot
study as a miniature version of a main study run to test
whether components of the main study work together,
while feasibility studies are pieces of research done before
a main study to answer the question “Can this study be
done?”. According to these definitions both pilot and feasi-
bility studies play a preliminary role in the design stage of
a subsequent larger trial, and do not themselves address
efficacy.
Arain et al [4] comment that researchers applying for
funding for trials inadequately powered to address clini-
cally meaningful hypotheses may adopt the designation
of a pilot study in the hope of a more favourable review.
When studies are prepared for publication authors may
similarly believe that labeling a small trial as a pilot
increases its chance of acceptance. Although Arain et al
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nals did not encourage publication of pilot studies
because of their perceived lack of rigour, it is possible
that other journals are more accommodating. In an edi-
torial in the journal Circulation, Loscalzo [7] proposed a
binary classification: trials designated ap r i o r ias pilots,
and those redefined a posteriori. During a five year period
41 pilot trials were published in the journal. Many had
been designated as pilots at the request of the editorial
office to alert readers to uncertainty in the generalizabil-
ity of their results and their preliminary and exploratory
nature. Such a policy is likely to result in trials primarily
addressing efficacy being described as pilots, contrary to
the NIHR and other recent definitions.
In comparison to the well established pathways of devel-
opment for pharmaceuticals, prior to 2000 there was little
specific guidance on the development of procedures
involved in trials of non-pharmacological interventions,
possibly because of their complex and heterogeneous nat-
ure. The MRC guidelines for the evaluation of complex
interventions published in 2000 [8] and revised in 2009 [9]
emphasize the importance of testing procedures before
planning an evaluation, and also the circular nature of
development, feasibility and piloting, evaluation, imple-
mentation, and further development. There is no specific
guidance for non-pharmacological interventions that do
not meet the MRC definition of complexity. In this paper
we review a random sample of 50 papers reporting rando-
mized controlled trials (RCTs) published in journals cov-
ered by the MEDLINE and EMBASE databases where
authors described their trial as a ‘pilot’ or addressing ‘feasi-
bility’ in the title. We review papers published between
2000 and 2009, the ten years following the publication of
the first MRC guidelines on complex interventions. We
examine stated objectives, results and conclusions drawn,
and in particular whether these relate to methodological
issues, efficacy or safety/toxicity: comparisons are drawn
between papers reporting drug and non-drug trials.
Methods
We searched the EMBASE and MEDLINE databases on
29
th July 2010 to identify papers reporting parallel group
trials with one or both of the words ‘Pilot’ and ‘Feasibility’
in the title. To be included, papers had to be published
between 2000 and 2009, written in English, studying
humans and indexed as an RCT. Using computer gener-
ated random numbers we selected 50 of those identified
for full review [10-59]. The sample size was chosen taking
into account resources available and the detailed review
required, it allows percentages between 10% and 17.5% to
be estimated with a 95% confidence interval (CI) of ± 10%.
The search was repeated on the 21
st February 2011 to gain
am o r ec o m p l e t ee s t i m a t eo ft h en u m b e ro fr e l e v a n t
papers in 2009: two papers were selected from those
identified on this date to replace papers found to be ineli-
gible at a late stage.
A form was designed to document characteristics of the
selected papers. It was tested by all three authors on
three randomly selected papers which were not part of
the main review sample. Minor modifications were made
after the first two papers of the main sample had been
reviewed. We defined drug trials as those involving the
administration of a discrete chemical entity, substance, or
biological agent by mouth or other route, for example by
injection. Questions on the form related to: any blinding
and in particular double blinding; the numbers of active
and placebo/control arms; whether multiple centres were
involved (sometimes deduced from the number of insti-
tutional review boards mentioned); the target and actual
sample sizes; and any justification given for the target
sample size.
Research objectives stated in the Abstract and Introduc-
tion sections were coded as relating to methodological
issues, efficacy, or safety/toxicity, as were statements sum-
marizing results and conclusions chosen for inclusion in
the Abstract. Objectives had to be explicitly stated, it was
not enough for the reviewer to deduce what the objectives
might have been from results presented, or conclusions
drawn. Efficacy conclusions in the Abstract were rated as
indicating that the experimental intervention had not been
shown to have benefit or had no benefit, that it showed
promise, or that it showed actual benefit. The accuracy of
conclusions drawn by the authors was not verified. An
example of an efficacy conclusion in the Abstract rated as
indicating the intervention had not been shown to have
benefit or had no benefit is
“With the numbers studied, we failed to find a signif-
icant difference between the two groups; thus we have
no evidence of a benefit from botulinum toxin injec-
tion in the treatment of chronic tennis elbow“ [34];
one rated as indicating the intervention to have pro-
mise is
“Therefore, the colonic colplasty seems to be an
attractive pouch design because of its feasibility, sim-
plicity, and effectiveness.” [31];
and one rated as indicating the intervention to have
actual benefit is
“Sleep educational programs for secondary students
are recommended to improve information about
sleep.” [23].
Numerical results presented in the Results sections were
classified as relating to methodological issues, efficacy, or
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experiencing methodological problems or side effects, or
numerical summaries of statistical findings: text state-
ments that a procedure was feasible for example were not
enough to qualify as a result. Methodological results were
recorded separately for: recruitment, retention, compli-
ance/adherence to intervention, blinding procedures,
acceptability of the intervention to participants, other
aspects of the intervention, outcome assessment, logistics
of the randomization procedure, acceptability of trial
procedures, or the logistics of multi-centre procedures.
Selection of these topics was in part based on the issues
that Lancaster et al [2] list as constituting pilot studies.
We checked the Methods sections to see whether metho-
dological results were reported there, sometimes they
formed part of a CONSORT flowchart [60] for example.
Depth of coverage was coded as none, brief, detailed or
tabulated/graphical presentation. Significance tests and
CIs presented for efficacy outcomes were examined to see
whether they indicated between or within group signifi-
cant differences, but no attempt was made to judge which
findings were the primary evaluation of efficacy.
In the Discussion sections we again rated coverage of
methodological issues, efficacy, and safety/toxicity as
none, minimal, substantial, or the major focus of the
section. An example of discussion concerning methodo-
logical issues rated as minimal was
“The results are promising but not conclusive because
of the low numbers of patients studied, and we
recommend that a sufficiently powered study should
be performed.” [29];
and the following example was rated as substantial
“In order to show an assumed clinically relevant dif-
ference of 2 kg, with an 80% power and a type-I error
of 5%, 300 patients would be needed (150 in each
treatment group). If a subsequent study were to be
planned, it would be advisable to use the mean
change in grip strength as a primary variable because
the variability for this parameter was lowest in the
present study and it came close to identifying a signifi-
cant difference between groups (p = 0.196). In addi-
tion, grip strength is a quantifiable measurement of
effect, unlike the more subjective measurement of
pain.” [34].
The NIHR definitions indicate that pilot and feasibility
studies should be preliminary research prior to a main
study: we were therefore interested in whether authors
stated they were conducting a further trial (or were
scheduled to start one in the near future). If this was
mentioned it was usually in the Discussion section.
S i n c et h ea b o v et w oq u o t e sw e r et h eo n l ym e n t i o no f
future trials in each paper we did not consider either set
of authors to be actually conducting a future trial.
Comments in the Discussion concerning lack of power
or small sample size were noted.
Finally we recorded whether Conclusions sections
contained statements concerning methodological issues,
efficacy, or safety/toxicity. The Conclusion section could
be a specifically labelled section, a paragraph of the Dis-
cussion clearly listing conclusions, or presented as a
box: where there was no such section missing was
coded not the absence of a relevant conclusion.
The 50 papers were assessed by MS and difficulties aris-
ing were discussed with RMP and MW. Blyth-Still-Casella
95% CIs for single percentages and exact CIs for Rate
Ratios (RR) were obtained in StatXact [61]. Ordinal ratings
were compared between groups in Mann-Whitney U tests,
and percentages in exact Pearson’s chi-squared tests.
Results
After removal of duplicates our EMBASE/MEDLINE
search identified 3,581 papers (see Table 1). In order to
achieve a sample of 50 suitable papers a further 25 were
rejected for the reasons shown in Table 1. The final two
papers were excluded at a late stage because the words
‘pilot’ or ‘feasibility’ in the title did not relate to the trial
(in one ‘pilot’ was part of the name of the intervention
and in the other the intervention aimed to increase the
feasibility of a further procedure). When the search was
repeated on 21
st February 2011 the number of papers
had increased to 3652 (Figure 1). The frequency of papers
rose steeply with time. Although not formally evaluated it
is likely that, as in the sample of papers selected for
review, a third would not meet our eligibility criteria. The
majority (3120, 85%) of papers had the word ‘pilot’ in the
title; 479 (13%) had the word ‘feasibility’; and 50 (1%) had
both.
Table 2 describes the characteristics of the trials
reported in the papers selected for review [10 - 59] The
percentages with ‘pilot’ or ‘feasibility’ in the title were
similar to those amongst the 3,652 papers identified. In
four titles [32,41,45,46] the word ‘feasibility’ described
the trial: in the other four [30,38,42,43] it described the
intervention. Over half of the trials, (28, 56%, CI 41% to
70%) evaluated drugs. The majority (29, 58%) were single
centre trials, 19 (38%) were multi-centre, and in two
cases we were unable to determine whether one or more
centres were involved. Most trials consisted of one active
and one control arm, but the drug trials often had active
arms at several doses and 8/28 (29%) had no placebo
arm. One non-drug trial was unusual because it had 12
arms. It was a factorial trial carried out over the internet
with one factor being six ways of presenting treatment
effects to participants crossed with a second factor being
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MEDLINE/EMBASE search Number of papers
1 pilot.ti 40741
2 feasibility.ti 16179
3 1o r2 56430
4 limit 3 to randomized controlled trial 7553
5 limit 4 to english language 7398
6 limit 5 to humans 7348
7 limit 6 to yr = “2000 - 2009” 5965
8 remove duplicates from 7 3581
RANDOM SAMPLE OF PAPERS
Papers randomly selected from 8 75
EXCLUDED PAPERS (n = 25)
Remove cross-over trials (n = 14) 61
Remove trials with only one arm (n = 1) 60
Remove historically controlled trials (n = 2) 58
Remove non-randomized trials (n = 2) 56
Remove letters (n = 1) 55
Remove brief reports (n = 1) 54
Remove study protocols (n = 1) 53
Remove review articles (n = 1) 52
Remove articles where ‘pilot’ or ‘feasibility’ in the trial did not relate to the trial (n = 2) 50
Figure 1 Frequencies of papers identified with ‘pilot’, ‘feasibility’ or both in the title (searched on 21
st February 2011).
Shanyinde et al. BMC Medical Research Methodology 2011, 11:117
http://www.biomedcentral.com/1471-2288/11/117
Page 4 of 11the order of eliciting their understanding of treatment
consequences from visual analogue or category rating
scales [20]. The drug trials were more likely than non-
drug trials to incorporate blinding (75% vs 32%, RR 2.4,
CI 1.3 to 4.7), or to be described as double blinded (54%
vs 5%, RR 11.8, CI 2.3 to 167.6). Most papers didn’tj u s -
tify the sample size; 11 presented a power calculation
which in all but one related to efficacy (the exception
being the internet trial which related to correlation
between alternative scales for assessing understanding of
treatment consequences [20]); and 3 included non-statis-
tical justifications (one stated the size to be adequate for
a pilot study providing the chance to see if there were
trends between active and placebo arms [53], the second
didn’t present a power calculation on the grounds that it
was a pilot study but the size of 60 was based on safety
data for other indications and was an achievable number
[28], while the third was designed as a pilot, no signifi-
cant differences were anticipated, and the size was cho-
sen based on feasibility for a single-site study [10]). The
median achieved sample size was 34 but there were three
large trials: the first recruited 425 adolescents to test a
sleep educational program in secondary schools [23]; the
internet trial [20] recruited 998 people after sending out
approximately 700,000 emails; and 3,318 people were
recruited from 653,417 information packs mailed in a
screening trial for lung cancer [32].
Figure 2 presents the percentage of papers in which
methodological issues, efficacy, and safety/toxicity were
explicitly stated as objectives, addressed with numerical
results, discussed to an extent rated greater than minimal,
or where conclusions were drawn. High percentages relat-
ing to efficacy can be seen for both drug and non-drug
trials. The drug trials also addressed safety/toxicity issues,
whereas the non-drug trials were more likely to addition-
ally address methodological issues. In Table 3 the specific
methodological issues are detailed. Recruitment and reten-
tion were frequently, though not always addressed to
some extent: most papers with tabular/graphical presenta-
tion covered the issues in a CONSORT flowchart. Compli-
ance/adherence to intervention was included in a few
CONSORT flowcharts, but was more frequently addressed
in text. Other aspects of intervention examined included
cost and duration. The one paper that presented tabu-
lated/graphical results relating to outcome assessment
portrayed values elicited with category rating scales
m a p p e do n t oav i s u a la n a l o g u es c a l ef o r m a t[ 2 0 ] .W e
rated the average costs per randomization presented in
one paper [49] as detailed results relating to randomiza-
tion procedures, the two papers with brief results on this
topic commented on a failure in the randomization service
[12] and gave numbers and reasons why potential partici-
pants missed being randomized [38]. Although our sample
included 19 multi-centre trials only one presented
Table 2 Characteristics of the drug and non-drug trials
Drug
(n = 28)
Non-drug
(n = 22)
Index word in title pilot 25 (89%) 17 (77%)
feasibility 1 (4%) 4 (18%)
both 2 (7%) 1 (5%)
Number of centres single 18 (64%) 11 (50%)
multi-centre 10 (36%) 9 (41%)
unclear/not stated 0 2 (9%)
Active arms 1 15 (54%) 16 (73%)
2 85
3 40
4 10
12 01
Control/placebo arm 20 (71%) 18 (82%)
Any blinding mentioned 21 (75%) 7 (32%)
Stated to be double blinded 15 (54%) 1 (5%)
Target sample size not stated 18 (64%) 15 (68%)
stated with no justification 2 (7%) 1 (5%)
non-statistical justification 3 (11%) 0
statistical justification 5 (18%) 6 (27%)
Actual sample size median 34 30.5
min-max 10-87 6-3318
sample size not stated n=1 n=0
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of cooperation between different centres [49]).
The emphasis on efficacy demonstrated in Figure 2 is
explored in Table 4. Statistically significant differences
between groups were reported in 19 (38%) of papers,
but we were unable to determine whether these related
to pre-stated primary outcomes or were opportunistic
reporting. Where significant differences between groups
were not reported sometimes significant within group
differences were. In 43 (86%) the Discussion section
included a statement that the trial was too small: a simi-
lar statement was made in 24 (48%) of the Abstracts.
Efficacy was addressed in the Discussion by all authors
and in 26 (52%) it was the major focus. The take home
message on efficacy from the Abstract section was rated
to be that the intervention was beneficial in 24 (48%),
and showed promise in 13 (26%). In 8 (16%, CI 7% to
28%) of the Abstracts there was no mention of efficacy.
As shown in Table 5, while most authors (39, 78%, CI
64% to 88%) did mention methodological issues in the Dis-
cussion it was often to a minimal extent. We rated the dis-
cussion to be substantial or the major focus of the section
for 28 (56%, CI 41% to 70%), and covered to greater depth
in the papers reporting non-drug compared to drug trials
(P = 0.002). Most papers mentioned future trials but it was
usually to an extent we rated as minimal: as with the cover-
age of feasibility issues more generally the depth of discus-
sion concerning future trials was rated to be greater in the
paper reporting non-drug trials (P = 0.002). Papers report-
ing non-drug trials were also more likely to include a
methodological conclusion in the Conclusions section if
there was one (P = 0.022), and in the Abstract (P = 0.031).
The groups were similar with respect to whether the
authors were actually conducting a subsequent trial with
only 6 (12%, CI 5% to 23%) overall stating that one was
underway or scheduled to start in the near future.
Figure 2 Percentage of papers in which feasibility, efficacy and safety/toxicity objectives, results, discussion or conclusions were
presented (percentages for the Conclusions section based on the 32 papers including one).
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Page 6 of 11Table 3 Methodological issues that were addressed numerically with frequencies of participants or other statistical
methods
Issue Drug
(n = 28)
Non-drug
(n = 22)
Recruitment none 21 (75%) 9 (41%)
brief coverage 5 (18%) 4 (18%)
detailed coverage 1 (4%) 3 (14%)
tabulated/figure 1 (4%) 6 (27%)
Retention none 16 (57%) 9 (41%)
brief coverage 6 (21%) 7 (32%)
detailed coverage 00
tabulated/figure 6 (21%) 6 (27%)
Compliance/adherence with the intervention none 14 (50%) 10 (46%)
brief coverage 7 (25%) 7 (32%)
detailed coverage 5 (18%) 1 (5%)
tabulated/figure 2 (7%) 4 (18%)
Blinding procedures brief coverage 2 (7%) 1 (5%)
Acceptability of the intervention to participants brief coverage 1 (4%) 1 (5%)
detailed coverage 0 1 (5%)
tabulated/figure 0 2(9%)
Other aspects of the intervention brief coverage 1 (4%) 2 (9%)
detailed coverage 0 1 (5%)
tabulated/figure 0 2 (9%)
Outcome assessment brief coverage 1 (4%) 4 (18%)
detailed coverage 1 (4%) 0
tabulated/figure 0 1 (5%)
Randomization procedure brief coverage 0 2 (9%)
detailed coverage 0 1 (5%)
Acceptability of trial procedures brief coverage 1 (4%) 0
detailed coverage 0 3 (14%)
Logistics of multi-centre procedures detailed coverage 0 1 (4%)
Table 4 Results, discussion and conclusions concerning efficacy
Drug
(n = 28)
Non-drug
(n = 22)
ABSTRACT
Take home message no mention of efficacy 4 (14%) 4 (18%)
not shown to have benefit/no benefit 4 (14%) 1 (5%)
intervention shows promise 8 (29%) 5 (23%)
intervention beneficial 12 (43%) 12 (55%)
Mentioned that further/larger trials needed 13 (46%) 11 (50%)
RESULTS
Statistically significant none 12 (43%) 9 (43%)
results relating to efficacy within groups only 5 (18%) 4 (19%)
between groups 11 (39%) 8 (38%)
1
DISCUSSION
Extent of discussion about minimal 1 (4%) 3 (14%)
efficacy substantial 11 (39%) 9 (41%)
major focus of section 16 (57%) 10 (46%)
Mentioned that the sample size was too small 24 (86%) 19 (88%)
1 - One paper reporting a non-drug trial didn’t report any significance tests or confidence intervals and was excluded from these figures.
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For the main part the pilot and feasibility trials in our
review did not primarily address methodological issues.
Although lessons learnt about planning trials were dis-
cussed in the majority of papers it was often to an extent
we rated as minimal, and in only 6 (12%) of papers was it
stated that the authors were actually conducting a subse-
quent trial or about to start one. This frequency is not dis-
similar to the 9% of pilot studies reviewed by Lancaster et
al [2], subsequently found to have been followed by a lar-
ger study [4]. Even though authors themselves may not
proceed to a larger RCT it is possible that others reading
the paper will. Our impression was that many of the trials
fell into the latter of Loscalzo’s [9] two classes: namely
those designated as pilots a posteriori possibly after failing
to demonstrate the hoped for effects or because of inade-
quate sample size. In all but one of the 11 papers including
a power calculation, sample size was determined to
achieve power in testing efficacy. In other papers it was
i m p o s s i b l et ob es u r ew h a ta priori objectives were from
the published paper alone, but since methodological issues
were discussed to greater depth in the non-drug trials,
they are more likely to fall into Loscalzo’s class of a priori
pilot trials. Even amongst the non-drug trials there was
generally an emphasis on efficacy.
We interpreted efficacy as the examination of change in
an outcome variable not clearly related to safety/toxicity.
The final group of scientific objectives for pilot studies
listed by Thabane et al [5] includes obtaining estimates
of the treatment effect and its variance. Thabane et al
also discuss the distinction between pilot and proof-of-
concept studies which they define as a clinical trial car-
ried out to determine if a treatment (drug) is biologically
active or inactive. Arnold et al [3] include the assessment
of mechanisms, possibly using surrogate measures, as a
legitimate objective of pilot trials, to establish proof-of-
principal and potential efficacy. Many of the papers in
our review may lie on the margins between pilot and
proof-of-concept investigations and their emphasis on
efficacy should perhaps be interpreted in this light, how-
ever none were described as proof-of- either concept or
principal studies in their title [10 - 59], though one [42]
was described as a phase II pilot study.
We specifically selected pilot/feasibility trials that
incorporated random allocation. Many methodological
issues do not need to be examined in the context of an
RCT: for example larger numbers would be available
from routinely collected data; it is generally easier to con-
duct a single group study; and greater depth of under-
standing of the acceptability of interventions is obtained
from qualitative research. Some issues that cannot be
satisfactorily investigated other than in the context of a
randomized trial are the percentage consenting to rando-
mization, retention in intervention and control groups,
whether blinding can be maintained, and whether all
components of the protocol work together. Given the
burden of research governance concerning RCTs, it
would seem sensible to evaluate specific aspects of a pro-
tocol using simpler studies wherever possible. In Table 6
we indicate with a tick methodological issues that require
piloting in the context of an RCT, those marked with a
cross could be assessed in other types of feasibility study.
Thabane et al [5] recommend that explicit criteria indi-
cating that a subsequent trial is feasible should be stated:
they describe the criteria set out in advance for proceed-
ing from the pilot to the main Prophylaxis of
Table 5 Discussion and conclusions about planning further studies
Drug
(n = 28)
Non-drug
(n = 22)
P
Coverage of feasibility issues in the Discussion section none 8 (29%) 3 (14%) 0.002
1
minimal 9 (32%) 2 (9%)
substantial 9 (32%) 7 (32%)
major focus of section 2 (7%) 10 (46%)
Extent of discussion or recommendations about planning future trials none 6 (21%) 1 (5%) 0.002
1
minimal 21 (75%) 13 (59%)
substantial 1 (5%) 8 (36%)
major focus of section 00
One or more conclusion about
methodological issues in a conclusions section
7/14 (50%) 16/18 (89%) 0.022
3
One or more conclusion about
methodological issues in the Abstract
5 (18%) 11 (50%) 0.031
3
Conducting a subsequent trial
or about to start one in the near future
3 (11%) 3 (14%) 1.000
3
1 - Mann Whitney U test.
2 - Restricted to papers with a Conclusions section.
3 - Exact Pearson’s chi-squared test.
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[62], also reviewed by Arnold et al [3]. In contrast, Gar-
dener et al [63] describe a case study where unanticipated
problems arising during a pilot lead to abandoning a sub-
sequent RCT even though pre-stated objectives indicated
the methodology to be feasible. They identify the avail-
ability of funding and the contemporary health service
environment as issues likely to impact on the decision to
proceed. We believe that studies evaluating the feasibility
of trial procedures are essentially exploratory in nature.
Researchers should examine carefully the success of pro-
cedures and react to unanticipated problems to get the
best possible design for their next trial. Aspects of the
design aren’t decided in isolation, predicted recruitment
under a set of eligibility criteria may be adequate if there
is a change in outcome variable for example. If extensive
changes are made it may be advisable to retest the feasi-
bility of the protocol.
Others have searched for pilot/feasibility trials adopting
different criteria leading to different populations of
papers surveyed. Lancaster et al [2] could find no gui-
dance on how to search MEDLINE for pilot/feasibility
trials, and restricted their search to papers in six top
ranking medical journals with the words ‘pilot’ or ‘feasi-
bility’ in the title, abstract or keywords: of the 115 hits
retrieved 25 (22%) were not suitable for a variety of rea-
sons. Arain et al [4] repeated Lancaster et al’s search
procedure seven years later with a rate of unsuitable
papers (30%) similar to ours of 33%. Arnold et al [3] initi-
ally searched MEDLINE for pilot trials in critical care
medicine, but then canvassed known clinical investigators
because of the poor indexing of pilot trials. They describe
five pilot trials fulfilling the requirements of either
addressing methodological issues relating to the feasibil-
ity of subsequent trials, or assessing mechanisms of inter-
vention. Reviews based on published papers do not
address internal pilots which continue into the main
phase and are unlikely to be reported separately, though
where a decision is taken not to continue the pilot phase
could be written up. We chose to include only full papers
in our study: different issues may arise amongst pilot or
feasibility trials that are published as letters or brief
reports. Sampling from all journals covered by MEDLINE
and EMBASE and restricted to trials incorporating ran-
dom allocation, the characteristics of the pilot/feasibility
trials we found is not unexpected. The majority bear little
resemblance to the recent definitions proposed for pilot/
feasibility studies.
Conclusions
Our main findings are that RCTs described by their
authors as pilots or addressing feasibility most com-
monly focus on efficacy, in just over a half (56%) were
issues that might inform the planning of a subsequent
Table 6 Methodological issues that need evaluation in the context of an RCT
Issue Needs to be evaluated in the context
of a randomized pilot trial
Comments
Sample size calculation ✗ The numbers in a pilot RCT are unlikely to be adequate to get accurate
estimates of effect size of variances.
Eligibility ✗
Recruitment ✓ Referrals from clinicians are likely to depend on the RCT context.
Consent ✓ Consent rates in the RCT context are unlikely to be accurately
estimated from asking about likely consent beforehand
Randomization procedures ✓
Blinding procedures ✓
Compliance/adherence to
intervention
✗ Though, this could potentially depend on preference amongst
interventions offered in the main trial
Acceptability of
intervention
✗ Though, this could potentially depend on preference amongst
interventions offered in the main trial
Cost and duration of
intervention
✗
Outcome assessment ✗
Selection of most
appropriate outcomes
✗
Retention ✓ Retention may differ between experimental and control groups, and
may depend on treatment preferences
Logistics of multi-centre
trial
✓
All components of the
protocol work together
✓
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Page 9 of 11trial addressed in reasonable depth. In addition to effi-
cacy pilot drug trials also addressed safety, while pilot
non-drug trials were more likely to additionally address
methodological issues. While the median sample size
was quite small at 34, there were three trials recruiting
over 100 participants, demonstrating that sample size
very much depends on circumstances even in the con-
text of pilot/feasibility trials.
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